• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Analysts are closely watching the Sun Pharma stock for what some say are prospects of the company's US business and the sustained thrust on its domestic formulations.

Some others expect the company to do well on the back of its domestic business, which focuses on niche, lifestyle segments. With the de-merger of its innovative R&D, the company may well be shielded from the risks involving the innovative R&D process, it is felt.

On Monday, the Sun Pharma stock closed on the BSE at Rs 894.85, down 2.5 per cent. At the current price, the stock is valued at about 27x fiscal 2007 and 23x fiscal 2008 fully diluted earnings.

Nilanjan Dey

More Stories on : Stock Markets | Stocks | Ear to the ground | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Rain in South to sustain for 4 more days

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line